// App-Quantinova.ai

1718 : Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index

Researchers

Presenter

  • Marianne B. Ashford

Principal Investigators

  • Srividya B. Balachander

  • Lorraine Graham

  • Iain Grant

  • Francis D. Gibbons

  • Kathryn J. Hill

  • Alexander R. Harmer

  • Sonya Gales

  • Sean Redmond

  • Brian Kelly

  • William McCoull

  • Shenghua Wen

  • Martin Wild

  • Eric Gangl

  • David J. Owen

  • Barry R. Davies

Medical Centers

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca, Waltham, MA

  • Straxcorp Pty Ltd, Melbourne, Australia

Locations

  • United Kingdom

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Thrombocytopenia

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 2

  • B-cell lymphoma-extra large

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved